GlassScriptPhysician profile
Raja Taunk
NPI 1073772976
$328,430.09
in general payments reported to CMS, 2019-2025
42 companies · $55K in 2025
The $55K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $13K · 2021: $23K · 2022: $46K · 2023: $58K · 2024: $113K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186K · Travel and Lodging: $19K · Consulting Fee: $12K · Food and Beverage: $9,315 · Education: $62.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,568.86 |
| Travel and Lodging | $18,929.46 |
| Consulting Fee | $11,715.00 |
| Food and Beverage | $9,314.70 |
| Education | $62.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $198,682.54 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $49,815.39 | 2019-2025 | Tremfya, Stelara, Erleada |
| Phathom Pharmaceuticals, INC. | $23,499.66 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $22,710.40 | 2019-2025 | Entyvio, Eohilia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $15,272.41 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,763.80 | 2019-2024 | Xifaxan, Trulance |
| Ferring Pharmaceuticals INC. | $4,413.09 | 2019-2024 | Rebyota |
| Celgene Corporation | $3,652.13 | 2019-2024 | Zeposia |
| Ardelyx, INC. | $1,654.80 | 2022-2025 | Ibsrela |
| Pfizer INC. | $932.95 | 2019-2025 | |
| Madrigal Pharmaceuticals | $402.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Echosens North America, INC. | $361.93 | 2019-2024 | Fibroscan |
| Intercept Pharmaceuticals, INC. | $318.69 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $311.47 | 2019-2024 | Sucraid |
| Genzyme Corporation | $247.16 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raja Taunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.